• By ICR Secretariat
  • Posted Monday, August 1, 2022

After failed Alzheimer's launch, Biogen writes off the remaining value of its Aduhelm inventory


Biogen is trying to escape the dark Aduhelm cloud hanging over its Alzheimer's disease drug launch. So far, the launch has triggered layoffs, a CEO switch and much more.